Navigation Links
Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
Date:11/3/2008

n, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements d
'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
2. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
3. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
6. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
7. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
8. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
9. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  The Dr. Samadi Prostate ... is now offering a full suite of new genetic testing ... a biopsy, for diagnosing prostate cancer. ... of genetic tests for assessing the risk and optimizing the ... "We,re very excited to now offer these revolutionary genetic ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by filmmakers, the ... dynamic collection of legal medical cannabis stories ever assembled. , Cannavoices profiles ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... B2. Under the terms of the agreement, MediVet will acquire the rights to ... (UCMSCs). MB-007 is currently in pre-clinical development as a potential next-generation treatment for ...
(Date:6/29/2015)... 29, 2015  AACC, a global scientific and ... laboratory medicine, is pleased to announce that the ... , has increased to 7.9 in the 2014 ... Clinical Chemistry in the top 3% ... influence of the research it publishes on laboratory ...
Breaking Biology Technology:New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... , , BOTHELL, Wash., Aug. 7 ... reported financial results for the three and six months ended June ... Morra, SCOLR Pharma,s President and CEO, said, "We continue to advance ... release ibuprofen. These potential partners have been committing resources to due ...
... EXTON, Pa., Aug. 7 Kensey Nash Corporation ... the distribution rights, along with the trademark, inventory and ... product line. Under the terms of the agreement, the ... existing OsseoFit distribution agreement. Pursuant to the agreement, following ...
... , CORAL GABLES, Fla., Aug. 7 Catalyst Pharmaceutical Partners, Inc. ... and six months ended June 30, 2009. , , ... For the quarter ended June 30, 2009, the Company reported a net loss ... loss of $2,377,440, or $0.19 per basic and diluted share for the same ...
Cached Biology Technology:SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 8Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 5Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 6Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 7
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
(Date:6/23/2015)...   MedNet Solutions , an innovative SaaS-based ... of clinical research, is pleased to announce that ... company,s intuitive, flexible and affordable cloud-based eClinical technology ... Award by the American Business Awards (SM) ... The American Business Awards are considered the nation,s ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... September 8, 2008For allergy sufferers, the choice all too ... curtains or anything that could trigger indoor allergens. ... with the launch of Clorox® Anywhere® Anti-Allergen Fabric Spray, ... fabric surfaces in the home. Clorox® Anywhere® ...
... Francis S. Collins, M.D., Ph.D., a physician-geneticist and ... with the new Inamori Ethics Prize from the Inamori ... Reserve University. Modeled after the Nobel and Kyoto ... Inamori Ethics Prize instead honors outstanding international ethical leaders. ...
... headed by Prof. Daniel Rosenfeld of the Institute of ... come up with a surprising finding to the disputed ... The conclusion: both can be true, depending on local ... is one with significant consequences in an era of ...
Cached Biology News:The Clorox Company's new indoor allergen product reduces common indoor allergens up to 90 percent 2Leader of Human Genome Project honored with the Inamori Ethics Prize 2Dirty air brings rain -- then again, maybe not 2Dirty air brings rain -- then again, maybe not 3
Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
Mycoplasma and virus tested...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
Biology Products: